Coffee and Alzheimer's Disease: Animal and Cellular Evidence

Coffee: Emerging Health Effects and Disease Prevention

Volumn , Issue , 2012, Pages 77-96

  Miller, Marshall G ^a   Shukitt Hale, Barbara ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

Caffeine in coffee; Cellular, animal models; Coffee and AD; Cognitive decline; MAPT phosphorylated; Neuroprotective effects

Indexed keywords

EID: 84886036601     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119949893.ch4     Document Type: Chapter

References (123)

1. National Center for Health Statistics. Leading causes of death. http://www.cdc.gov/nchs/fastats/ lcod.htm (accessed August 11, 2010)
2. Eskelinen, M. H., et al. Midlife coffee and tea drinking and the risk of late-life dementia: A populationbased CAIDE study. J. Alzheimers Dis. 2009, 16, 85-91.
3. Maia, L., de Mendonca, A. Does caffeine intake protect from Alzheimer's disease. Eur. J. Neurol. 2002, 9, 377-382.
4. van Gelder, B. M., et al. Coffee consumption is inversely associated with cognitive decline in elderly European men: the FINE study. Eur. J. Clin. Nutr. 2007, 61, 226-232.
5. Ritchie, K., et al. The neuroprotective effects of caffeine: a prospective population study (the Three City Study). Neurology 2007, 69, 536-545.
6. Santos, C., et al. Caffeine intake is associated with a lower risk of cognitive decline: a cohort study from Portugal. J. Alzheimers Dis. 2010, 20, S175-S185.
7. Blennow, K., de Leon, M. J., Zetterberg, H. Alzheimer's disease. Lancet 2006, 368, 387-403.
8. Alzheimer, A. Uber eine eigenartige Erkankung der Hirnrinde. Psychiatr. 1907, 64, 146.
9. Alzheimer, A., Stelzmann, R. A., Schnitzlein, H. N., Murtagh, F. R. An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin. Anat. 1995, 8, 429-431.
10. Ferri, C. P., et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366, 2112-2117.
11. Ramesh, B. N., et al. Neuronutrition and Alzheimer's disease. J. Alzheimers Dis. 2010, 19, 1123-1139.
12. Wahlin, T. R., Byrne, G. J. Personality changes in Alzheimer's disease: a systematic review. Int. J. Geriatr. Psych. 2011, 26, 1019-1029.
13. Karttunen, K., et al. Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer's disease. Int. J. Geriatr. Psych. 2010, 26, 473-482.
14. Mega, M. S., Cummings, J. L., Fiorello, T., Gornbein, J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1995, 46, 130-135.
15. Kalbe, E., et al. Anosognosia in very mild Alzheimer's disease but not in mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 2005, 19, 349-356.
16. Perl, D. P. Neuropathology of Alzheimer's disease. Mt. Sinai J. Med. 2010, 77, 32-42.
17. Mott, R. T., Hulette, C. M. Neuropathology of Alzheimer's disease. Neuroimag. Clin. N. Am. 2005, 15, 755-765.
18. Terry, R. D., et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991, 30, 572-580.
19. Braak, H., Braak, E. Neuropathological staging of Alzheimer-related changes. Acta. Neuropathol. 1991, 82, 239-259.
20. Selden, S. C., Polard, T. D. Phosphorylation of microtubule-associated proteins regulates their interaction with actin filaments. J. Biol. Chem. 1983, 258, 7064-7071.
21. Dawson, H. N., et al. Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease. Neuroscience 2010, 169, 516-531.
22. Goedert, M., Spillantini, M. G. A century of Alzheimer's disease. Science 2006, 314, 777-781.
23. Arriagada, P. V., Growdon, J. H., Hedley-White, T., Hyman, B. T. Neurofibrillary tangles and not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992, 42, 1681-1688.
24. Hof, P. R., et al. Neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch. Neurol. 1995, 52, 81-88.
25. Kang, J., et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325, 733-736.
26. Vassar, R., et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286, 735-741.
27. Selkoe, D. J., et al. The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Ann. NY Acad. Sci. 1996, 777, 57-64.
28. Prelli, F., Castano, E., Glenner, C. G., Frangione, B. Differences between vascular and plaque core amyloid in Alzheimer's disease. J. Neurochem. 1988, 51, 648-651.
29. Hardy, J., Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297, 353-356.
30. Ferreira, S. T., Vieira, M. N. N., De Felice, F. G. Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. Life 2007, 59, 332-345.
31. Nunomura, A., et al. Oxidative damage is the earliest event in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 2001, 60, 759-767.
32. Castellani, R. J., Lee, H. G., Perry, G., Smith, M. A. Antioxidant protection and neurodegenerative disease: the role of amyloid-beta and tau. Am. J. Alzheimers Dis. Other Demen. 2006, 21, 126-130.
33. El Khoury, J., et al. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature 1996, 382, 716-719.
34. Rogers, J., Lue, L. F. Microglial chemotaxis, activation, and phagocytosis of amyloid β-peptide as linked phenomena in Alzheimer's disease. Neurochem. Int. 2001, 39, 333-340.
35. Kopek, K. K., Caroll, R. T. Alzheimer's beta-amyloid peptide 1-42 induces a phagocytic response in murine microglia. J. Neurochem. 1998, 71, 2123-2131.
36. Frackowiak, J., et al. Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce beta-amyloid fibrils. Acta Neuropathol. 1992, 84, 225-233.
37. Weldon, D. T., et al. Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of select population of neurons in the rat CNS in vivo. J. Neurosci. 1998, 18, 2161-2173.
38. Tuppo, E. E., Arias, H. R. The role of inflammation in Alzheimer's disease. Int. J. Biochem. Cell Biol. 2005, 37, 289-305.
39. Whitehouse, P. J., et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 1981, 10, 122-126.
40. Perry, E. K., et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br. Med. J. 1978, 2, 1457-1459.
41. Serretti, A., Olgiati, P., de Ronchi, D. Genetics of Alzheimer's disease: a rapidly evolving field. J. Alzheimers Dis. 2007, 12, 73-92.
42. Auffret, A., Mariani, J., Rovira, C. Age-related progressive synaptic dysfunction: the critical role of presenilin 1. Rev. Neurosci. 2010, 21, 239-250.
43. Levy-Lahad, E., et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995, 269, 973-977.
44. Rogaev, E. I., et al. Familial Alzheimer's disease in kindred with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995, 376, 775-778.
45. Strittmatter, W. J., et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 1977-1981.
46. McKhann, G., et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984, 34, 939-944.
47. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision, Washington, DC: American Psychiatric Association; 1994.
48. World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: World Health Organization; 1992.
49. Summers, W. K. Tacrine in the treatment of Alzheimer's disease. Med. Sentinel 2000, 5, 15-18.
50. Potter, P. E. Investigational medications for treatment of patients with Alzheimer disease. J. Am. Osteopath. Assoc. 2010, 110(9 Suppl 8), S27-S36.
51. Minati, L., Edginton, T., Bruzzone, M. G., Giaccone, G. Current concepts in Alzheimer's disease: a multidisciplinary review. Amer. J. Alzheimers Dis. Other Dem. 2008, 24, 95-121.
52. van Dam, D., de Deyn, P. P. Drug discovery in dementia: the role of rodent models. Nat. Rev. Drug Discov. 2006, 5, 956-970.
53. Götz, J., Ittner, L. M. Animal models of Alzheimer's disease and frontotemporal dementia. Nat. Rev. Neurosci. 2008, 9, 532-544.
54. Harkany, T., et al. Neuroprotective approaches in experimental models of β-amyloid neurotoxicity: relevance to Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 1999, 23, 963- 1008.
55. Walsh, D. M., et al. Naturally secreted oligomers of amyloid β protein inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416, 535-539.
56. Kakeda, T., Hosokawa, M., Higuchi, K. Senescence-accelerated mouse (SAM): a novel murine model of senescence. Exp. Gerontol. 1998, 32, 105-109.
57. McGowen, E., Eriksen, J., Hutton, M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet. 2006, 22, 281-289.
58. Villanueva, C. M., et al. Total and specific fluid consumption as determinants of bladder cancer risk. Int. J. Cancer 2006, 118, 2040-2047.
59. Liu, Y. M., Shawuti, Y. Pharmacology of Uighur. Wulumaqi, China: Xinjiang People's Publishing House; 1985, p. 267.
60. Arendash, G. W., et al. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain β-amyloid production. Neuroscience 2006, 142, 941-952.
61. Chu, Y., et al. Roasted coffees high in lipophilic antioxidants and chlorogenic acid lactones are more neuroprotective than green coffees. J. Agric. Food Chem. 2009, 57, 9801-9808.
62. Cho, E. S., et al. Attenuation of oxidative neuronal cell death by coffee phenolic phytochemicals. Mutat. Res. 2009, 661, 18-24.
63. Bauer, A. R., et al. The effects of prolonged coffee intake on genetically identical mice. Life Sci. 1977, 21, 63-70.
64. Miura, Y., Ono, K., Okauchi, R., Yagasaki, K. Inhibitory effect of coffee on hepatoma proliferation and invasion in culture and on tumor growth, metastasis and abnormal lipoprotein profiles in hepatomabearing rats. J. Nutr. Sci. Vitaminol. 2004, 50, 38-44.
65. Hasegawa, R., et al. Analysis of the potential carcinogenicity of coffee and its related compounds in a medium-term liver bioassay of rats. Food Chem. Toxicol. 1995, 33, 15-20.
66. Green, K. N., et al. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J. Neurosci. 2006, 26, 9047-9056.
67. Yamato, T., et al. Modulation of the stress response by coffee: an in vivo microdialysis study of hippocampal serotonin and dopamine levels in rat. Neurosci. Lett. 2002, 332, 87-90.
68. Tse, S. Y. Coffee contains cholinomimetic compound distinct from caffeine. I: purification and chromatographic analysis. J. Pharm. Sci. 1991, 80, 665-669.
69. Tse, S. Y. Cholinomimetic compound distinct from caffeine contained in coffee. II: Muscarinic actions. J. Pharm. Sci. 1992, 81, 449-452.
70. Ferruzzi, M. G. The influence of beverage composition on delivery of phenolic compounds from coffee and tea. Physiol. Behav. 2010, 100, 33-41.
71. Smith, A. Caffeine. In: Nutritional Neuroscience. Leiberman, H. R., Kanarek, R. B., Prasad, C., eds. Boca Raton: CRC Press; 2005, pp. 341-356.
72. Ciruela, F., et al. Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J. Neurosci. 2006, 26, 2080-2087.
73. Fredholm, B. B., et al. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 1999, 51, 83-133.
74. Björklund, O., et al. Decreased behavioral activation following caffeine, amphetamine and darkness in A3 adenosine receptor knock-out mice. Physiol. Behav. 2008, 95, 668-676.
75. Rahman, A. The role of adenosine in Alzheimer's disease. Curr. Neuropharm. 2009, 7, 207-216.
76. Querfurth, H. W., Jiang, J., Geiger, J. D., Selkoe, D. J. Caffeine stimulates amyloid β-peptide release from β-amyloid precursor protein-transfected HEK293 cells. J. Neurochem. 1997, 69, 1580- 1591.
77. Dall'Igna, O. P., et al. Neuroprotection by caffeine and adenosine A2A receptor blockade of β-amyloid neurotoxicity. Brit. J. Pharmacol. 2003, 138, 1207-1209.
78. Costenla, A. R., Cunha, R. A., de Mendonca, A. Caffeine, adenosine receptors, and synaptic plasticity. J. Alzheimers Dis. 2010, 20, S25-S34.
79. Takahashi, R. N., Pamplona, F. A., Prediger, R. D. Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. Front. Biosci. 2008, 13, 2614-2632.
80. Prasanthi, J. R. P., et al. Caffeine protects against oxidative stress and Alzheimer's disease-like pathology in rabbit hippocampus induced by cholesterol-enriched diet. Free Radic. Biol. Med. 2010, 49, 1212-1220.
81. Prediger, R. D. S., Batista, L. C., Takahashi, R. N. Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats involvement of adenosine A1 and A2A receptors. Neurobiol. Aging 2005, 26, 957-964.
82. Arendash, G. W., et al. Caffeine reverses cognitive impairment and decreases brain amyloid-β levels in aged Alzheimer's disease mice. J. Alzheimers Dis. 2009, 17, 661-680.
83. Cao, C., et al. Caffeine suppresses amyloid-β levels in plasma and brain of Alzheimer's disease transgenic mice. J. Alzheimers Dis. 2009, 17, 681-697.
84. Johansson, B., Georgiev, V., Kuosmanen, T., Fredholm, B. Long-term treatment with some methylxanthines decreases the susceptibility to bicuculline- and pentylenetetrazol-induced seizures in mice. Relationship to c-fos expression and receptor binding. Eur. J. Neurosci. 1996, 8, 2447-2458.
85. Arendash, G.W., Cao, C. Caffeine and coffee as therapeutics against Alzheimer's disease. J. Alzheimers Dis. 2010, 20, S117-S126.
86. Cunha, R. A., Agostinho, P. M. Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. J. Alzheimers Dis. 2010, 20, S95-S116.
87. Clifford, M. N., et al. Characterization by LC-MS(n) of four new classes of chlorogenic acids in green coffee beans: dimethoxycnnamoylquinic acids, diferuloylquinic acids, caffeoyldimethoxycinnamoylquinic acids, and feruloyl-dimethoxycinnamoylquinic acids. J. Agric. Food Chem. 2006, 54, 1957-1969.
88. Higdon, J. V., Frei, B. Coffee and health: a review of recent human research. Crit. Rev. Food Sci. Nutr. 2006, 46, 101-123.
89. Herrmann, K. Occurrence and content of hydroxycinnamic and hydroxybenzoic acid compounds in foods. Crit. Rev. Food Sci. Nutr. 1989, 28, 315-347.
90. Trugo, L. C., Macrae, R. Chlorogenic acid composition of instant coffees. Analyst. 1984, 109, 263-266.
91. Moon, J. K., Yoo, H. S., Shibamoto, T. Role of roasting conditions in the level of chlorogenic acid content in coffee beans: correlation with coffee acidity. J. Agric. Food Chem. 2009, 57, 5365- 5369.
92. Clifford, M. N. Chlorogenic acids and other cinnamates: nature, occurrence, dietary burden, absorption and metabolism. J. Sci. Food Agric. 2000, 80, 1033-1043.
93. Kim, D. O., Jeong, S. W., Lee, C. Y. Antioxidant capacity of phenolic phytochemicals from various cultivars of plums. Food Chem. 2003, 81, 321-326.
94. Dupas, C., et al. Chlorogenic acid is poorly absorbed, independently of the food matrix: a Caco-2 cells and rat chronic absorption study. Mol. Nutr. Food. Res. 2006, 50, 1053-1060.
95. Gonthier, M., et al. Chlorogenic acid bioavailability largely depends on its metabolism by the gut microflora in rats. J. Nutr. 2003, 133, 1853-1859.
96. Ito, H., et al. Chlorogenic acid and its metabolite m-coumaric acid evoke neurite outgrowth in hippocampal neuronal cells. Biotechnol. Biochem. 2008, 72, 885-888.
97. Kim, S. S., et al. Neuroprotective effects of 3,5-dicaffeolylquinic acid on hydrogen peroxide-induced cell death in SH-SY5Y cells. Phytother. Res. 2005, 19, 243-245.
98. Nakajima,Y., Shimazawa,M., Mishima, S., Hara, H.Water extract of propolis and its main constituents, caffeoylquinic acid derivatives, exert neuroprotective effects via antioxidant actions. Life Sci. 2007, 80, 370-377.
99. Chang, W., et al. Chlorogenic acid attenuates adhesion molecules upregulation in IL-1β-treated endothelial cells. Eur. J. Nutr. 2010, 49, 267-275.
100. Boettler, U., et al. Coffee constituents as modulators of Nrf2 nuclear translocation and ARE (EpRE)-dependent gene expression. J. Nutr. Biochem. 2010, 22, 426-440.
101. Bouayed, J., et al. Chlorogenic acid, a polyphenol and Prunus domestica (Mirabelle), with coupled anxiolytic and antioxidant effects. J. Neur. Sci. 2007, 262, 77-84.
102. Kwon, S., et al. Neuroprotective effects of chlorogenic acid on scopolamine-induced amnesia via anti-acetylcholinesterase and anti-oxidative activities in mice. Behav. Pharmacol. 2010, 649, 210-217.
103. Rice-Evans, C. A., Miller, M. J., Paganga, G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic. Biol. Med. 1996, 20, 933-956.
104. Sato, Y., et al. In vitro and in vivo antioxidant properties of chlorogenic acid and caffeic acid. Int. J. Pharm. 2011, 403, 136-138.
105. Nardini, M., et al. Effect of caffeic acid dietary supplementation on the antioxidant defense system in rat: an in vivo study. Arch. Biochem. Biophys. 1997, 342, 157-160.
106. Wayner, D. D. M., et al. The relative contributions of vitamin E, urate, ascorbate and proteins to the total peroxyl radical-trapping antioxidant activity of human blood plasma. Biochim. Biophys. Acta. 1987, 924, 408-419.
107. Huang, J., de Paulis, T., May, J. M. Antioxidant effects of dihydrocaffeic acid in human EA.hy926 endothelial cells. J. Nutr. Biochem. 2004, 15, 722-729.
108. de Paulis, T., et al. Dicinnamoylquinides in roasted coffee inhibit the human adenosine transporter. Eur. J. Pharmacol. 2002, 442, 215-223.
109. Stadler, R. H., et al. Alkylpyridiniums: 1. Formation and model systems via thermal degradation of trigonelline. J. Agric. Food. Chem. 2002a, 50, 1200-1206.
110. Stadler, R. H., et al. Alkylpyridiniums: 2. Isolation and quantification in roasted and ground coffees. J. Agric. Food. Chem. 2002b, 50, 1200-1206.
111. Lang, R., Yagar, E. F., Eggers, R., Hofmann, T. Quantitative investigation of trigonelline, nicotinic acid, and nicotinamide in foods, urine, and plasma by means of LC-MS/MS and stable isotope dilution analysis. J. Agric. Food. Chem. 2008, 56, 11114-11121.
112. Tohda, C., Nakamura, N., Komatsu, K., Hattori, M. Trigonelline-induced neurite outgrowth in human neuroblastoma SK-N-SH cells. Biol. Pharm. Bull. 1999, 22, 679-682.
113. Tohda, C., Kuboyama, T., Komatsu, K. Search for natural products related to regeneration of the neuronal network. Neurosignals 2004, 14, 34-45.
114. Urgert, R., Katan, M. B. The cholesterol-raising factor from coffee beans. Annu. Rev. Nutr. 1997, 17, 305-324.
115. Urgert, R., et al. Separate effects of the coffee diterpenes cafestol and kahweol on serum lipids and liver aminotransferases. Am. J. Clin. Nutr. 1997, 65, 519-524.
116. Lee, K. J., Jeong, H. G. Protective effects of kahweol and cafestol against hydrogen peroxide-induced oxidative stress and DNA damage. Toxicol. Lett. 2007, 173, 80-87.
117. Hwang, Y. P., Jeong, H. G. The coffee diterpenes kahweol induces heme oxygenase-1 via the PI3K and p38/Nrf2 pathway to protect human dopaminergic neurons from 6-hydroxydopamine-derived oxidative stress. FEBS Letters 2008, 582, 2655-2662.
118. Kim, J.Y., Jung, K. S., Jeong, H. G. Suppressive effects of the kahweol and cafestol on cyclooxygenase-2 expression in macrophages. FEBS Letters. 2004, 569, 321-326.
119. Shen, T., et al. Cafestol, a coffee-specific diterpenes, is a novel extracellular signal regulated kinase inhibitor with AP-1-targeted inhibition of prostaglandin E2 production in lipopolysaccharide-activated macrophages. Biol. Pharm. Bull. 2010, 33, 128-132.
120. Trinh, K., et al. Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson's disease through an Nrf2-dependent mechanism. J. Neurosci. 2010, 30, 5525-5532.
121. Dostal, V., Roberts, C. M., Link, C. D. Genetic mechanisms of coffee extract protection in a Caenorhabditis elegans model of β-amyloid peptide toxicity. Genetics 2010, 186, 857-866.
122. Maeso, N., et al. Capillary electrophoresis for caffeine and pyroglutamate determination in coffees Study of the in vivo effect on learning and locomotor activity in mice. J. Pharm. Biomed. Anal. 2006, 41, 1095-1100.
123. Antonelli, T., et al. Pyroglutamic acid administration modifies the electrocorticogram and increases the release of acetylcholine and CABA from the guinea-pig cerebral cortex. Pharmacol. Res. Commun. 1984, 16, 189-197.